Generic cancer drugs that we can trust

Generics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. ItÂ’s good news for greater access, but patients want reassurance that switching to generics wonÂ’t put them at risk.

The side effects of targeted drugs are poorly documented, and their impact on patients frequently seriously underestimated and undertreated. Efforts to address these issues could improve survival as well as quality of life.

Walking the line between quick access and evidence

How do you decide which new cancer drugs to approve, when statistical certainty takes too long to wait for and essential evidence on quality of life is hard to measure? The head of the cancer section at the European Medicines Agency is keen to explain his approach.

Better outcomes data lead to better outcomes

Caring for one of our own

When youÂ’re caring for a patient and friend, who was recently your colleague, working out boundaries and negotiating the particular privileges and pressures of caring for them can be hard. The problem was explored in a Schwartz Center Round* at the Massachusetts General Hospital.

European School of Oncology - ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.

Euro-Arab School of Oncology (EASO) - is an exclusive initiative of the European School of Oncology (ESO) to promote and facilitate the cultural and educational exchange between Europe and the Arab world in the field on cancer medicine.